Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEAM plus PBSCT versus sequential high-dose chemotherapy followed by BEAM plus PBSCT in relapsed Hodgkin lymphoma
ISRCTN72542803Phase 3Completed
- Sponsor
- German Hodgkin Study Group
- Start
- Jul 2001
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carmustine, etoposide, cytarabine, melphalan, cyclophosphamide and 5 more in Hodgkin lymphoma (HL), sponsored by German Hodgkin Study Group. Started Jul 2001; status: completed.
02
Drugs
carmustineetoposidecytarabinemelphalancyclophosphamide
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on ISRCTN72542803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN72542803.